Previous 10 | Next 10 |
FRAMINGHAM, MA / ACCESSWIRE / October 29, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specif...
The following slide deck was published by Xenetic Biosciences, Inc. in conjunction with this Read more ...
Bionano Genomics (NASDAQ: BNGO ) -31% . More news on: Bionano Genomics, Inc., Pareteum Corporation, Xenetic Biosciences, Inc., Stocks on the move, Read more ...
Gainers: Viveve Medical (NASDAQ: VIVE ) +91% . Achillion Pharmaceuticals (NASDAQ: ACHN ) +71% . Regional Health Properties (NYSEMKT: RHE ) +53% . Xenetic Biosciences (NASDAQ: XBIO ) +44% . Assembly Biosciences (NASDAQ: ASMB ) +30% . Ideal Power (NASDAQ: IPWR ) +29% . Aethlon Me...
Viveve Medical (NASDAQ: VIVE ) +109% on robust volume on no particular news. More news on: Viveve Medical, Inc., Achillion Pharmaceuticals, Inc., Ideal Power Inc., Stocks on the move, Read more ...
Presentation with Live Audio Webcast on Wednesday, October 23 rd at 2:45 PM PT FRAMINGHAM, MA / ACCESSWIRE / October 16, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antige...
Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART development plan Completion of recent financing expected to f...
Xenetic Biosciences (NASDAQ: XBIO ): Q2 GAAP EPS of -$1.56. More news on: Xenetic Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Building momentum with recent acquisition of innovative XCART platform technology and closing of $15 million underwritten public offering - Corporate strategy shift with entry into the CAR T space positions Company to drive significant value for shareholders - Company executes o...
Gainers: NovaBay Pharmaceuticals (NYSEMKT: NBY ) +34% . Medley Management (NYSE: MDLY ) +33% . Pieris Pharmaceuticals (NASDAQ: PIRS ) +24% . Daxor (NYSEMKT: DXR ) +18% . Oasmia Pharmaceutical AB (NASDAQ: OASM ) +17% . Acasti Pharma (NASDAQ: ACST ) +15% . Mylan N.V. (NASDAQ: MYL...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...